본문 바로가기

Michaelis-Menten elimination kinetics of etanercept, rheumatoid arthritis biologics, after intravenous and subcutaneous administration in rats

문서 유형
연구출판물 · 학술지 논문
등재
SCIEScopus
저널 순위
JCR Q3Scopus Q3
피인용
Web of Science 4
JCR IF
JCR 2015 1.68
ISSN
0378-7966

저자

  1. Lee, Byung-yo제1저자충남대학교, Coll Pharm, Daehak Ro 79, KO
  2. Kwon, Kwang-il충남대학교, Coll Pharm, Daehak Ro 79, KO
  3. 김민수교신저자부산대학교, 약학대학, 약학부, 제약학전공, KO
  4. Baek, In-hwan경성대학교, Coll Pharm, 309 Suyeong Ro, KO

초록

Etanercept was approved by the Food and Drug Administration (FDA) in 2010 as a biologic agent for the treatment of rheumatoid arthritis (RA). The aim of the study was to investigate the pharmacokinetic properties of etanercept after intravenous and subcutaneous injection in rats. The plasma concentration of etanercept was determined using an enzyme-linked immunosorbent assay (ELISA). Intravenous and subcutaneous administration of 2 mg/kg of etanercept to rats showed that etanercept was slowly absorbed (time to reach the peak drug concentration [T (max)] = 1.60 days, bioavailability [F] = 47.18 %) and slowly eliminated (half-life [t (1/2)], 2.33 days after intravenous administration and 3.31 days after subcutaneous administration). The area under the curve values on day 13 (AUC(13day)) were 121.25 +/- 14.37 and 48.56 +/- 6.78 mu g day/mL after intravenous and subcutaneous administration, respectively. A two-compartment model with Michaelis-Menten elimination kinetics (V (max) = 94.28 A mu g/day; K (m) = 10.88 A mu g/mL) was used to describe the pharmacokinetic profile of etanercept. Our results describe the pharmacokinetic profile of etanercept, and these results could be used for the development of etanercept biosimilars.

키워드

EtanerceptPharmacokineticsMichaelis-Menten kineticsSubcutaneousFUSION PROTEINPHARMACOKINETICS

식별자

WoS UID
000380254700013